Lecanemab Conversion From Accelerated To Full Approval Could Be Among Fastest Ever
Executive Summary
Biogen/Eisai’s Phase III data is on track for a Q1 2023 submission, potentially just weeks after lecanemab is expected to gain accelerated approval for early Alzheimer’s.